Of the three Covid-19 vaccine candidates pending approval from regulators in India, two are being manufactured locally.
One of them is Covishield, a vaccine developed by Oxford University and AstraZeneca and produced by the Serum Institute of India, the largest vaccine maker in the world.
The other is India’s first homegrown coronavirus vaccine, Covaxin, developed jointly by Bharat Biotech and the government-run Indian Council of Medical Research.
Pfizer India has also applied for emergency use authorization for the coronavirus vaccine developed by Pfizer and BioNTech.
Adar Poonawalla, Chief Executive Officer of the Serum Institute of India, said his company is currently producing 50 to 60 million doses of Covishield per month, and production will be scaled up to 100 million doses in 2021.
He said, “I think everybody is aware the Ministry of Health wants 300 to 400 million doses by July 2021, so we’re trying to get to that target.”